A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 with BIBF 1120 in Patients with Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2009
At a glance
- Drugs Afatinib; Nintedanib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 May 2009 Planned number of patients changed from 24 to 28 as reported by ClinicalTrials.gov.
- 01 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.